Literature DB >> 10941548

Left ventricular myocardial remodeling and contractile state in chronic aortic regurgitation.

K Taniguchi1, T Kawamaoto, S Kuki, T Masai, M Mitsuno, S Nakano, Y Kawashima, H Matsuda.   

Abstract

BACKGROUND: In chronic aortic regurgitation, eccentric hypertrophy, with combined concentric hypertrophy of the left ventricle, is an important adaptive response to volume overload, which in itself is a compensatory mechanism for permitting the ventricle to normalize its afterload and to maintain normal ejection performance (physiologic hypertrophy). However, progressive dilatation of the left ventricle leads to depressed left ventricular (LV) contractility and myocardial structural changes, including cellular hypertrophy and interstitial fibrosis (pathological hypertrophy). HYPOTHESIS: The study was undertaken to determine the relationship between left ventricular myocardial structure and contractile function in 14 patients with chronic aortic regurgitation by cardiac catheterization and endomyocardial biopsies.
METHODS: Myocardial cell diameter and percent interstitial fibrosis were obtained from biopsy samples. Contractile function was evaluated from the ratio of end-systolic wall stress to end-systolic volume index (ESS/ESVI) and the ejection fraction-end-systolic stress (EF-ESS) relationship, which was obtained from 30 normal control subjects.
RESULTS: Myocardial cell diameter correlated significantly with the ESVI (r = 0.72, p < 0.005), ejection fraction (r = -0.58, p < 0.05), and ESS/ESVI (r = -0.58, p < 0.05). The percent interstitial fibrosis also correlated inversely with ESS/ESVI (r = -0.71, p < 0.005). Compared with very few patients with an ESVI < 70 ml/m2, the majority of patients with ESVI > or = 70 ml/m2 had a cell diameter of > or = 30 microns and a percent interstitial fibrosis of > or = 10%. The nine patients who had depressed contractile function, as assessed from the EF-ESS relationship, had a higher percent interstitial fibrosis (p < 0.05) than five patients showing a normal EF-ESS relationship, despite the fact that there was no significant difference in myocardial cell diameter between them. Thus, advanced cellular hypertrophy and excessive interstitial fibrosis were significantly and independently associated with myocardial contractile dysfunction and appeared to be responsible for ventricular remodeling.
CONCLUSION: Our findings suggest that in many patients with aortic regurgitation, eccentric hypertrophy changes its nature from physiologic to nonphysiologic during the earlier stages in the course of the disease rather than during the stage described previously.

Entities:  

Mesh:

Year:  2000        PMID: 10941548      PMCID: PMC6654784          DOI: 10.1002/clc.4960230812

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  5 in total

1.  Exploratory assessment of left ventricular strain-volume loops in severe aortic valve diseases.

Authors:  Hugo G Hulshof; Arie P van Dijk; Keith P George; Maria T E Hopman; Dick H J Thijssen; David L Oxborough
Journal:  J Physiol       Date:  2017-03-09       Impact factor: 5.182

2.  The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation.

Authors:  Bachar El Oumeiri; Philippe van de Borne; Géraldine Hubesch; Antoine Herpain; Filippo Annoni; Pascale Jespers; Constantin Stefanidis; Kathleen Mc Entee; Frédéric Vanden Eynden
Journal:  Physiol Rep       Date:  2021-08

3.  Evaluation and management of aortic valve and root disease.

Authors:  John B de Graft-Johnson; Thomas G Gleason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-12

4.  Myocardial Integrated Backscatter in Obese Adolescents: Associations with Measures of Adiposity and Left Ventricular Deformation.

Authors:  Lijian Xie; Elim Man; Pik-To Cheung; Yiu-Fai Cheung
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

5.  Myocardial Scar and Mortality in Chronic Aortic Regurgitation.

Authors:  Maan Malahfji; Alpana Senapati; Bhupendar Tayal; Duc T Nguyen; Edward A Graviss; Sherif F Nagueh; Michael J Reardon; Miguel Quinones; William A Zoghbi; Dipan J Shah
Journal:  J Am Heart Assoc       Date:  2020-11-26       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.